Guoliang Zhang

USPTO Granted Patents = 17 (Patent Applications = 16)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 34(Granted Patents)

Company Filing History:

Microsoft Technology Licensing, LLC

patents

1 out of 22

Beigene Switzerland Gmbh

patents

Years Active: 2012-2025

where 'Filed Patents' based on already Granted Patents

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12281119 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2025-04-21),

2. 11534431 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer (2022-12-27),

3. 11472811 - Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist (2022-10-18),

4. 10882856 - 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases (2021-01-05),

5. 10864203 - Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer (2020-12-15),

6. 10647714 - 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases (2020-05-12),

7. 10576087 - Fused tricyclic compounds as Raf kinase inhibitors (2020-03-03),

8. 10562899 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors (2020-02-18),

9. 10351559 - Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore (2019-07-16),

10. 10280163 - 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases (2019-05-07),

11. 10208038 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors (2019-02-19),

12. 9920055 - Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors (2018-03-20),

13. 9895376 - Fused tricyclic compounds as Raf kinase inhibitors (2018-02-20),

14. 9670203 - Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors (2017-06-06),

15. 9273046 - Fused tricyclic compounds as Raf kinase inhibitors (2016-03-01),

Sure, I can help you with that!

Title: The Innovator: Guoliang Zhang's Journey of Transformative Inventions

Introduction: Guoliang Zhang, a prolific inventor based in Beijing, China, has made his mark in the field of oncology with a series of groundbreaking patents.

Latest Patents: Zhang's recent patents showcase his dedication to advancing cancer treatment. He introduced a pharmaceutical combination involving a PD-1 antagonist and a RAF inhibitor, demonstrating synergistic efficacy in combating cancer. Additionally, he unveiled pyrazolotriazolopyrimidine derivatives as effective A2A receptor antagonists for treating cancer.

Career Highlights: With an impressive portfolio of 16 patents, Guoliang Zhang has left an indelible impact on the industry. Notably, he has contributed significantly to Beigene Ltd. and Microsoft Technology Licensing, LLC, where his innovative spirit flourished.

Collaborations: Zhang's success is also attributed to his fruitful collaborations with esteemed colleagues such as Changyou Zhou and Shaohui Wang. Together, they have pushed the boundaries of medical science and drug development.

Conclusion: Guoliang Zhang's inventive prowess and unwavering commitment to revolutionize cancer treatment have solidified his position as a pioneering figure in the realm of oncology. His relentless pursuit of innovation continues to inspire and shape the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.